NCT07246278

Celecoxib in Parkinson Disease as Adjuvant Therapy

Evaluating Safety and Efficacy of Celecoxib in Patients With PD.

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	Levodopa Carbidopa	Carbidopa/levodopa is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
DRUG	Celecoxib 200mg	Celecoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1)

Timeline

• Start date: 2025-11-20
• Primary completion: 2026-11-20
• Completion: 2026-11-28
• First posted: 2025-11-24
• Last updated: 2025-12-05

Locations

1 site across 1 country: Egypt